Dual-time-point PET/CT to differentiate fluorodeoxyglucose-avid hiatal hernia from mediastinal malignancy

Clinical Nuclear Medicine

Volumn 31, Issue 8, 2006, Pages 492-496

  Shen, Daniel Hueng Yuan ^a   Chang, Tsun Hou ^a   Lin, Ming Hsien ^b   Cheng, Cheng Yi ^a   Liu, Chang Hsien ^a   Huang, Weng Sheng ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Fluorodeoxyglucose; Hiatal hernia; Positron emission tomography

Indexed keywords

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; ESOPHAGUS TUMOR; HIATUS HERNIA; HUMAN; IMAGE ANALYSIS; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; MEDIASTINUM CANCER; MEDICAL ASSESSMENT; MOUTH CANCER; PATIENT REFERRAL; POSITRON EMISSION TOMOGRAPHY;

AGED; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL DISEASES; FLUORODEOXYGLUCOSE F18; HERNIA, HIATAL; HUMANS; LIVER NEOPLASMS; MALE; MEDIASTINAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33748186963     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000227495.73875.52     Document Type: Article

References (12)

1. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point F-18-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412.
2. Alavi A, Gupta N, Alberini JL, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med. 2002;32:293.
3. Wudel LJ Jr, Delbeke D, Morris D, et al. The role of F-18- fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg. 2003;69:117.
4. Jeng LB, Changlai SP, Shen YY, et al. Limited value of F-18-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers. Hepatogastroenterology. 2003;50:2154.
5. Jang KM, Lee KS, Lee SJ, et al. The spectrum of benign esophageal lesions: imaging findings. Korean J Radiol. 2002;3:199.
6. Fukunaga T, Okazumi S, Koide Y, et al. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med. 1998;39:1002.
7. Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F, et al. Clinical value of F-18-fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg. 2000;231:380.
8. Ahn SH, Scheiner JD, Noto RB. Uptake of F-18 FDG by a hiatal hernia. Clin Nucl Med. 2002;27:733.
9. Bhargava P, Zhuang H, Alavi A. Hiatal hernia mimics centrally necrotic cancer in the lung on FDG positron emission tomographic imaging. Clin Nucl Med. 2003;28:347.
10. Ak I, Ozalp S, Yalcin OT, et al. Uptake of 2-F-18-fluoro-2-deoxy-D- glucose in uterine leiomyoma: imaging of four patients by coincidence positron emission tomography. Nucl Med Commun. 2004;25:941.
11. Beaulieu S, Rubin B, Djang D, et al. Positron emission tomography of schwannomas: emphasizing its potential in preoperative planning. AJR Am J Roentgenol. 2004;182:971.
12. Hanemann CO, Kaempchen KE, Kaufmann D, et al. Fludeoxyglucose F-18 positron emission tomography and computed tomography of a giant retroperitoneal schwannoma occurring in a patient with neurofibromatosis type 2. Arch Neurol. 2005;62:674.